Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 20/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 19/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23957942 | 1.00 | MTNR1B (0.65) | MTNR1BMTNR1A | |
| SCHEMBL15142208 | 1.00 | MTNR1B (0.65) | MTNR1BMTNR1A | |
| Tasimelteon SCHEMBL3505912 | 0.79 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| Tasimelteon SCHEMBL3505909 | 0.79 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| Tasimelteon SCHEMBL15805116 | 0.79 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| Tasimelteon SCHEMBL23499868 | 0.79 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| Tasimelteon SCHEMBL17269306 | 0.79 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL6678547 | 0.79 | MTNR1B (0.67) | MTNR1BMTNR1A | |
| SCHEMBL6678551 | 0.79 | MTNR1B (0.67) | MTNR1BMTNR1A | |
| SCHEMBL6677292 | 0.79 | MTNR1B (0.74) | MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11090285-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210128517-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2021-05-06 | — | — | US | disclosed |
| US-10945988-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190133991-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2019-05-09 | — | — | US | disclosed |
| US-10179119-B2 | Method of treatment | VANDA PHARMACEUTICALS INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170239210-A1 | METHOD OF TREATMENT | VANDA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-9730910-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730910-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9060995-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9060995-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150025086-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150025086-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20140296331-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140296330-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140296330-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140296331-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS, INC. | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179119-B2 | Method of treatment | METTL3, MTNR1B, HCRTR2 | MTNR1B 2/4885MTNR1A 11/4885 |
| US-20140296330-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | MTNR1B 5/4885MTNR1A 4/4885 |
| US-20210128517-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | MTNR1B 5/4885MTNR1A 4/4885 |
| US-20190133991-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | MTNR1B 5/4885MTNR1A 4/4885 |
| US-20140296331-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | MTNR1B 5/4885MTNR1A 4/4885 |
| US-10945988-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | MTNR1B 5/4885MTNR1A 4/4885 |
| US-11090285-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | MTNR1B 5/4885MTNR1A 4/4885 |
| US-20150025086-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | MTNR1B 5/4885MTNR1A 4/4885 |
| US-20170239210-A1 | METHOD OF TREATMENT | METTL3, MTNR1B, HCRTR2 | MTNR1B 2/4885MTNR1A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.